Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: The investigation of Mitogen-Activated Protein kinase Phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging

Figure 4

Rosiglitazone regulates MMP-2 and CXCR4 expression via MKP-1 induction. (A) H441GL cells treated with different concentrations of rosiglitazone (RGZ, 0 to 30 μM) demonstrated a decrease in both MMP2- and CXCR4 protein expression levels accompanied by an increase in MKP-1 expression level in a dose-dependent fashion This effect was reversed when triptolide (TRP, a MKP-1 inhibitor at 10 ng/ml) was added (B) (C-D) As demonstrated by zymography, MMP-2 enzymatic activity was reduced by RGZ in a dose-dependent manner, and this reduction by RGZ could be reversed by the addition of triptolide (E-F) Corresponding in vitro invasion and migration assays also showed RGZ treatment decreased cellular mobility of H441GL cells Data expressed as mean ± SD (n = 3).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us